NL-OMON41720已完成2 期
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension - 0035/0100 (GS-US-357-1394) <br>
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible
- •for participation in this study:;1) Have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
- •2) Man or woman age 18 through 75 years
- •3) Diagnosis of one of the following:
- •c) Drug- and toxin-induced PAH
- •d) PAH associated with one of the following:
- •i) Connective tissue disease (CTD; e.g. limited scleroderma, diffuse scleroderma, mixed CTD systemic lupus erythematous or overlap syndrome),
- •ii) HIV infection
- •iii) Congenital heart defects, repaired greater than 1 year prior to screening (atrial septal defects, ventricular septal defects, and patent ductus arteriosus)
- •4) Confirm the diagnosis of PAH and meet all of the following hemodynamic criteria by means of a screening RHC completed prior to randomization:
- •a) Mean pulmonary artery pressure (mPAP) of * 25 mmHg
- •b) Pulmonary vascular resistance (PVR) * 400 dyne*sec/cm5
- •c) Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) of * 12 mmHg if PVR * 400 and < 500 dynes*sec/cm5, or PCWP/LVEDP * 15 mmHg if PVR * 500 dynes*sec/cm5
- •5) Be able to walk a distance of at least 100 m during the screening visit 6-minute walk test (6MWT) and have screening and randomization visit 6MWD that do not vary by more than 10%
- •6) Have WHO Functional Class II or III symptoms at the screening visit, as assessed by the investigator
- •7) Meet the following criteria determined by pulmonary function tests completed no more than 24 weeks prior to screening, performed with or without bronchodilation:
- •a) Forced expiratory volume in one second (FEV1) * 55% of predicted normal
- •b) FEV1:FVC ratio * 0.60
- •8) Currently on a stable treatment regimen with one or more drugs approved for PAH. Stable therapy is defined as dosing of the same treatments for * 12 weeks prior to the screening RHC and at a stable dose for * 8 weeks prior to the screening RHC. Any instances where doses have been missed prior to RHC must be discussed with the medical monitor prior to performing the RHC.
- •9) If diagnosed with HIV, must have stable disease status. For this study, stable HIV status is defined as follows:
- •a) Stable treatment with HIV medications for at least 8 weeks prior to screening,
- •b) No active opportunistic infection during the screening period, and
- •c) No hospitalizations due to HIV for at least 4 weeks prior to screening
- •10) Have documented evidence of the exclusion of chronic thromboembolic pulmonary hypertension (CTEPH) by a negative or low probability lung ventilation/perfusion (V/Q) scan or
- •negative pulmonary arteriogram
- •11) Women of childbearing potential must have a negative serum pregnancy test at Screening
- •12) If engaged in heterosexual activity and of child-bearing potential, must agree to use protocol-specified method(s) of contraception
- •13) If participating in an exercise program for pulmonary rehabilitation, the program must have been initiated *12 weeks prior to screening, and subjects must agree to maintain the current
- •level of rehabilitation for the first 24 weeks of study treatment
- •14) If not participating in an exercise training program for pulmonary rehabilitation, must agree not to enroll in an exercise training program for pulmonary rehabilitation during the screening period and the first 24 wee
排除标准
- •Subjects who meet any of the following exclusion criteria are not to
- •be enrolled in this study:
- •15) Diagnosis of PAH associated with:
- •a) Significant venous or capillary involvement (PCWP > 15 mm Hg)
- •b) Pulmonary capillary hemangiomatosis
- •c) Portal hypertension
- •d) Unrepaired congenital heart defects
- •16) Pulmonary hypertension (PH) belonging to groups 2 to 5 of the 2013 NICE classification.
- •a) Group 2: PH due to left heart disease
- •b) Group 3: PH due to lung diseases and/or hypoxia
- •c) Group 4: Chronic thromboembolic pulmonary hypertension
- •d) Group 5: PH with unclear multifactorial mechanisms
- •17) Evidence of * 3 of the following left ventricular disease/dysfunction risk factors (a-d):
- •a) Body mass index (BMI) * 30
- •b) Established diagnosis of essential hypertension and active treatment during the 2 years prior to screening
- •c) Diabetes mellitus * any type
- •d) Historical evidence of significant coronary artery disease (CAD) established by any one of the following:
- •i) History of myocardial infarction
- •ii) History of percutaneous intervention
- •iii) Angiographic evidence of CAD (> 50% stenosis in at least one vessel), either by invasive angiography or by CT angiography
- •iv) Positive stress test with imaging (either pharmacologic or with exercise)
- •v) Previous coronary artery surgery
- •vi) Chronic stable angina
- •18) Left ventricular ejection fraction (LVEF) * 40% or clinically significant ischemic, valvular or constrictive heart disease
- •19) Receiving intravenous inotropes within 4 weeks prior to the screening visit (e.g. dopamine, dobutamine)
- •20) Receiving treatment with a strong CYP3A4 inhibitor (e.g. protease inhibitors, systemic ketoconazole or systemic itraconazole) within 2 weeks prior to randomization.
- •21) Receiving treatment with a strong CYP3A4 inducer (e.g. rifampin). within 2 weeks prior to randomization.
- •22) Uncontrolled hypertension (*180/110 mm Hg) at screening
- •23) End stage renal disease (receiving peritoneal dialysis, hemodialysis, or status after renal transplantation)
- •24) Severe liver disease (Child-Pugh Class C, with or without cirrhosis)
- •25) Severe arthritis, musculoskeletal problems, or morbid obesity that, in the opinion of the investigator, is the cause of the subject*s functional limitation and would affect the subject*s ability to perform or complete the 6MWT
- •26) History of malignancies within the past 5 years, except for a subject with localized, nonmetastatic basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix, or prostate cancer who is not currently or expected (during the study) to undergo radiation therapy, chemotherapy, hormonal treatment, and/or surgical intervention
- •27) Pregnant or breastfeeding; lactating females must agree to discontinue nursing before the study drug is administered
- •28) Demonstrated noncompliance with previous medical regimens
- •29) Current alcohol or substance abuse judged by the Investigator to potentially interfere with subject compliance or subject safety
- •30) Participation in a clinical study involving another investigational drug or device within 4 weeks before the screening visit. Current participation in a drug access study for an eligible PAH therapy in a country where the therapy is approved but not yet commercially available to the subject is allowed.
- •31) Known hypersensitivity to the study drug, the metabolites, or formulation
研究者
相似试验
进行中（未招募）
1 期
A clinical trial with GS-4997 in Subjects with Pulmonary Arterial HypertensioEUCTR2014-002131-34-DEGilead Sciences, Inc.120
进行中（未招募）
1 期
A clinical trial with GS-4997 in Subjects with Pulmonary Arterial HypertensioMen and women, ages 18 through 75 years, with a diagnosis of idiopathic PAH, heritable PAH or PAH associated with connective tissue disease (PAH-CTD), congenital heart defects (repaired), drug and toxin use, or human immunodeficiency virus (HIV) infection.MedDRA version: 18.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-002131-34-GBGilead Sciences, Inc.120
进行中（未招募）
1 期
A clinical trial with GS-4997 in Subjects with Pulmonary Arterial HypertensioMen and women, ages 18 through 75 years, with a diagnosis of idiopathic PAH, heritable PAH or PAH associated with connective tissue disease (PAH-CTD), congenital heart defects (repaired), drug and toxin use, or human immunodeficiency virus (HIV) infection.MedDRA version: 18.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-002131-34-NLGilead Sciences, Inc.120
进行中（未招募）
1 期
A clinical trial with GS-4997 in Subjects with Pulmonary Arterial HypertensioMen and women, ages 18 through 75 years, with a diagnosis of idiopathic PAH, heritable PAH or PAH associated with connective tissue disease (PAH-CTD), congenital heart defects (repaired), drug and toxin use, or human immunodeficiency virus (HIV) infection.MedDRA version: 18.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-002131-34-ITGilead Sciences, Inc.120
进行中（未招募）
1 期
A clinical trial with GS-4997 in Subjects with Pulmonary Arterial HypertensioMen and women, ages 18 through 75 years, with a diagnosis of idiopathic PAH, heritable PAH or PAH associated with connective tissue disease (PAH-CTD), congenital heart defects (repaired), drug and toxin use, or human immunodeficiency virus (HIV) infection.MedDRA version: 17.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-002131-34-ESGilead Sciences, Inc.120